A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine
Identifieur interne :
001860 ( PascalFrancis/Corpus );
précédent :
001859;
suivant :
001861
A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine
Auteurs : A. M. Bonnet ;
I. Serre ;
R. Marconi ;
Y. Agid ;
B. DuboisSource :
-
Movement disorders [ 0885-3185 ] ; 1995.
RBID : Pascal:95-0525473
Descripteurs français
- Pascal (Inist)
- Parkinson maladie,
Bromocriptine,
Agoniste,
Dopamine,
Pergolide,
Antiparkinsonien,
Lévodopa,
Essai,
Traitement,
Homme,
Evaluation performance.
English descriptors
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
A01 | 01 | 1 | | @0 0885-3185 |
---|
A03 | | 1 | | @0 Mov. disord. |
---|
A05 | | | | @2 10 |
---|
A06 | | | | @2 5 |
---|
A08 | 01 | 1 | ENG | @1 A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine |
---|
A11 | 01 | 1 | | @1 BONNET (A. M.) |
---|
A11 | 02 | 1 | | @1 SERRE (I.) |
---|
A11 | 03 | 1 | | @1 MARCONI (R.) |
---|
A11 | 04 | 1 | | @1 AGID (Y.) |
---|
A11 | 05 | 1 | | @1 DUBOIS (B.) |
---|
A14 | 01 | | | @1 INSERM Hôp. Salpêtrière, fédération neurologie, U289 @2 75013 Paris @3 FRA @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. |
---|
A14 | 02 | | | @1 Hôp. Salpêtrière, clin. maladies système nerveux @2 75013 Paris @3 FRA @Z 2 aut. |
---|
A20 | | | | @1 668-671 |
---|
A21 | | | | @1 1995 |
---|
A23 | 01 | | | @0 ENG |
---|
A43 | 01 | | | @1 INIST @2 20953 @5 354000054563720210 |
---|
A44 | | | | @0 0000 |
---|
A45 | | | | @0 22 ref. |
---|
A47 | 01 | 1 | | @0 95-0525473 |
---|
A60 | | | | @1 P @3 CC |
---|
A61 | | | | @0 A |
---|
A64 | 01 | 1 | | @0 Movement disorders |
---|
A66 | 01 | | | @0 USA |
---|
C02 | 01 | X | | @0 002B02B06 |
---|
C03 | 01 | X | FRE | @0 Parkinson maladie @5 01 |
---|
C03 | 01 | X | ENG | @0 Parkinson disease @5 01 |
---|
C03 | 01 | X | SPA | @0 Parkinson enfermedad @5 01 |
---|
C03 | 02 | X | FRE | @0 Bromocriptine @2 NK @2 FR @5 04 |
---|
C03 | 02 | X | ENG | @0 Bromocryptine @2 NK @2 FR @5 04 |
---|
C03 | 03 | X | FRE | @0 Agoniste @5 05 |
---|
C03 | 03 | X | ENG | @0 Agonist @5 05 |
---|
C03 | 03 | X | SPA | @0 Agonista @5 05 |
---|
C03 | 04 | X | FRE | @0 Dopamine @2 NK @2 FR @5 06 |
---|
C03 | 04 | X | ENG | @0 Dopamine @2 NK @2 FR @5 06 |
---|
C03 | 04 | X | SPA | @0 Dopamina @2 NK @2 FR @5 06 |
---|
C03 | 05 | X | FRE | @0 Pergolide @2 NK @2 FR @5 07 |
---|
C03 | 06 | X | FRE | @0 Antiparkinsonien @5 08 |
---|
C03 | 06 | X | ENG | @0 Antiparkinson agent @5 08 |
---|
C03 | 06 | X | SPA | @0 Antiparkinsoniano @5 08 |
---|
C03 | 07 | X | FRE | @0 Lévodopa @5 10 |
---|
C03 | 07 | X | ENG | @0 Levodopa @5 10 |
---|
C03 | 07 | X | SPA | @0 Levodopa @5 10 |
---|
C03 | 08 | X | FRE | @0 Essai @5 16 |
---|
C03 | 08 | X | ENG | @0 Test @5 16 |
---|
C03 | 08 | X | SPA | @0 Ensayo @5 16 |
---|
C03 | 09 | X | FRE | @0 Traitement @5 17 |
---|
C03 | 09 | X | ENG | @0 Treatment @5 17 |
---|
C03 | 09 | X | GER | @0 Aufbereiten @5 17 |
---|
C03 | 09 | X | SPA | @0 Tratamiento @5 17 |
---|
C03 | 10 | X | FRE | @0 Homme @5 20 |
---|
C03 | 10 | X | ENG | @0 Human @5 20 |
---|
C03 | 10 | X | SPA | @0 Hombre @5 20 |
---|
C03 | 11 | X | FRE | @0 Evaluation performance @5 23 |
---|
C03 | 11 | X | ENG | @0 Performance evaluation @5 23 |
---|
C03 | 11 | X | SPA | @0 Evaluación prestación @5 23 |
---|
C07 | 01 | X | FRE | @0 Système nerveux pathologie @5 37 |
---|
C07 | 01 | X | ENG | @0 Nervous system diseases @5 37 |
---|
C07 | 01 | X | SPA | @0 Sistema nervioso patología @5 37 |
---|
C07 | 02 | X | FRE | @0 Système nerveux central pathologie @5 38 |
---|
C07 | 02 | X | ENG | @0 Central nervous system disease @5 38 |
---|
C07 | 02 | X | SPA | @0 Sistema nervosio central patología @5 38 |
---|
C07 | 03 | X | FRE | @0 Encéphale pathologie @5 39 |
---|
C07 | 03 | X | ENG | @0 Cerebral disorder @5 39 |
---|
C07 | 03 | X | SPA | @0 Encéfalo patología @5 39 |
---|
C07 | 04 | X | FRE | @0 Extrapyramidal syndrome @5 40 |
---|
C07 | 04 | X | ENG | @0 Extrapyramidal syndrome @5 40 |
---|
C07 | 04 | X | SPA | @0 Extrapiramidal síndrome @5 40 |
---|
C07 | 05 | X | FRE | @0 Maladie dégénérative @5 41 |
---|
C07 | 05 | X | ENG | @0 Degenerative disease @5 41 |
---|
C07 | 05 | X | SPA | @0 Enfermedad degenerativa @5 41 |
---|
N21 | | | | @1 296 |
---|
|
Format Inist (serveur)
NO : | PASCAL 95-0525473 INIST |
ET : | A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine |
AU : | BONNET (A. M.); SERRE (I.); MARCONI (R.); AGID (Y.); DUBOIS (B.) |
AF : | INSERM Hôp. Salpêtrière, fédération neurologie, U289/75013 Paris/France (1 aut., 3 aut., 4 aut., 5 aut.); Hôp. Salpêtrière, clin. maladies système nerveux/75013 Paris/France (2 aut.) |
DT : | Publication en série; Courte communication, note brève; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1995; Vol. 10; No. 5; Pp. 668-671; Bibl. 22 ref. |
LA : | Anglais |
CC : | 002B02B06 |
FD : | Parkinson maladie; Bromocriptine; Agoniste; Dopamine; Pergolide; Antiparkinsonien; Lévodopa; Essai; Traitement; Homme; Evaluation performance |
FG : | Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative |
ED : | Parkinson disease; Bromocryptine; Agonist; Dopamine; Antiparkinson agent; Levodopa; Test; Treatment; Human; Performance evaluation |
EG : | Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease |
GD : | Aufbereiten |
SD : | Parkinson enfermedad; Agonista; Dopamina; Antiparkinsoniano; Levodopa; Ensayo; Tratamiento; Hombre; Evaluación prestación |
LO : | INIST-20953.354000054563720210 |
ID : | 95-0525473 |
Links to Exploration step
Pascal:95-0525473
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine</title>
<author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Hôp. Salpêtrière, fédération neurologie, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Serre, I" sort="Serre, I" uniqKey="Serre I" first="I." last="Serre">I. Serre</name>
<affiliation><inist:fA14 i1="02"><s1>Hôp. Salpêtrière, clin. maladies système nerveux</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marconi, R" sort="Marconi, R" uniqKey="Marconi R" first="R." last="Marconi">R. Marconi</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Hôp. Salpêtrière, fédération neurologie, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Hôp. Salpêtrière, fédération neurologie, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Hôp. Salpêtrière, fédération neurologie, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">95-0525473</idno>
<date when="1995">1995</date>
<idno type="stanalyst">PASCAL 95-0525473 INIST</idno>
<idno type="RBID">Pascal:95-0525473</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001860</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine</title>
<author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Hôp. Salpêtrière, fédération neurologie, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Serre, I" sort="Serre, I" uniqKey="Serre I" first="I." last="Serre">I. Serre</name>
<affiliation><inist:fA14 i1="02"><s1>Hôp. Salpêtrière, clin. maladies système nerveux</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marconi, R" sort="Marconi, R" uniqKey="Marconi R" first="R." last="Marconi">R. Marconi</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Hôp. Salpêtrière, fédération neurologie, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Hôp. Salpêtrière, fédération neurologie, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Hôp. Salpêtrière, fédération neurologie, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1995">1995</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Bromocryptine</term>
<term>Dopamine</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Performance evaluation</term>
<term>Test</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Bromocriptine</term>
<term>Agoniste</term>
<term>Dopamine</term>
<term>Pergolide</term>
<term>Antiparkinsonien</term>
<term>Lévodopa</term>
<term>Essai</term>
<term>Traitement</term>
<term>Homme</term>
<term>Evaluation performance</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA08 i1="01" i2="1" l="ENG"><s1>A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BONNET (A. M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SERRE (I.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MARCONI (R.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>AGID (Y.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DUBOIS (B.)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM Hôp. Salpêtrière, fédération neurologie, U289</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Hôp. Salpêtrière, clin. maladies système nerveux</s1>
<s2>75013 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>668-671</s1>
</fA20>
<fA21><s1>1995</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000054563720210</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>22 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>95-0525473</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Bromocryptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Agonist</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Agonista</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pergolide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Essai</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Test</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Ensayo</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Evaluation performance</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Performance evaluation</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Evaluación prestación</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>296</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 95-0525473 INIST</NO>
<ET>A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine</ET>
<AU>BONNET (A. M.); SERRE (I.); MARCONI (R.); AGID (Y.); DUBOIS (B.)</AU>
<AF>INSERM Hôp. Salpêtrière, fédération neurologie, U289/75013 Paris/France (1 aut., 3 aut., 4 aut., 5 aut.); Hôp. Salpêtrière, clin. maladies système nerveux/75013 Paris/France (2 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1995; Vol. 10; No. 5; Pp. 668-671; Bibl. 22 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Bromocriptine; Agoniste; Dopamine; Pergolide; Antiparkinsonien; Lévodopa; Essai; Traitement; Homme; Evaluation performance</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Bromocryptine; Agonist; Dopamine; Antiparkinson agent; Levodopa; Test; Treatment; Human; Performance evaluation</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<GD>Aufbereiten</GD>
<SD>Parkinson enfermedad; Agonista; Dopamina; Antiparkinsoniano; Levodopa; Ensayo; Tratamiento; Hombre; Evaluación prestación</SD>
<LO>INIST-20953.354000054563720210</LO>
<ID>95-0525473</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001860 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001860 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:95-0525473
|texte= A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine
}}
| This area was generated with Dilib version V0.6.29. Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024 | |